Trial Profile
A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Jun 2012 Status changed from recruiting to completed.
- 13 Jun 2012 Additional data were presented, according to an Azaya Therapeutics media release.
- 06 Dec 2011 Planned number of patients changed from 24 to 36, according to ClinicalTrials.gov.